Home » Private Sector » Cipla extends diagnostics portfolio, launches point-of-care testing device

Private Sector

Cipla extends diagnostics portfolio, launches point-of-care testing device


Cipla extends diagnostics portfolio

A point-of-care testing system for a variety of non-communicable illnesses and other medical disorders was introduced on Wednesday by pharmaceutical giant Cipla as part of its ongoing effort to increase its position in the diagnostics market.

Cipla’s device, known as Cippoint, is another addition to its line of diagnostics laboratory products. It offers a wide range of testing parameters, including markers for coagulation, thyroid function, infectious diseases, diabetes, cardiac markers, and metabolic and metabolic markers.

The gadget, according to the manufacturer, is recognized by the European In-Vitro Diagnostic Device Directive, guaranteeing accurate testing procedures. Healthcare workers can use Cippoint, an immunofluorescence-based quantitative analyser, to acquire test findings in 3 to 15 minutes, facilitating a quicker clinical decision-making process.

Cipla said Cippoint has an automated system and user-friendly interface that can be used even in rural areas, mobile vans, and remote areas with limited infrastructure. Cippoint aims to enable smaller healthcare establishments to provide an accurate point-of-care testing experience.


Achin Gupta, CEO of Cipla’s India Business, stated, “We are aggressively working on developing novel solutions that enable rapid and effective diagnosis, hence addressing gaps in the diagnostic ecosystem.

According to Cipla’s annual report, the business intends to develop solutions throughout the care continuum, from simple and early diagnosis to effective treatment and monitoring, during its three-year strategy from 2020 to 2023. In FY 2021–2022, the company also introduced a number of diagnostic tests (antibodies and fast antigen) related to COVID–19.

In its annual report, Cipla stated that it “continues to focus on realising commercial opportunities beyond respiratory and complex generics and injectables, especially in the space of co-developing biosimilars, inhalation devices, diagnostics solutions, new-age technology platforms, and digitised business models.”

According to a report published by Praxis Global Alliance, a global management consulting and advisory services firm, the Indian medical diagnostic industry is expected to grow at around 14%, reaching $20 billion by 2026 from $10 billion in 2021 as investments continue to flow in the diagnostic segment with pharma companies entering the space.